Your browser doesn't support javascript.
loading
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss, Andreas; Lorthiois, Edwige; Barys, Louise; Beyer, Kim S; Bomio-Confaglia, Claudio; Burks, Heather; Chen, Xueying; Cui, Xiaoming; de Kanter, Ruben; Dharmarajan, Lekshmi; Fedele, Carmine; Gerspacher, Marc; Guthy, Daniel Alexander; Head, Victoria; Jaeger, Ashley; Núñez, Eloísa Jiménez; Kearns, Jeffrey D; Leblanc, Catherine; Maira, Sauveur-Michel; Murphy, Jason; Oakman, Helen; Ostermann, Nils; Ottl, Johannes; Rigollier, Pascal; Roman, Danielle; Schnell, Christian; Sedrani, Richard; Shimizu, Toshio; Stringer, Rowan; Vaupel, Andrea; Voshol, Hans; Wessels, Peter; Widmer, Toni; Wilcken, Rainer; Xu, Kun; Zecri, Frederic; Farago, Anna F; Cotesta, Simona; Brachmann, Saskia M.
Afiliación
  • Weiss A; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Lorthiois E; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Barys L; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Beyer KS; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Bomio-Confaglia C; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Burks H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Chen X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Cui X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • de Kanter R; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Dharmarajan L; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Fedele C; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Gerspacher M; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Guthy DA; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Head V; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Jaeger A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Núñez EJ; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Leblanc C; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Maira SM; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Murphy J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Oakman H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Ostermann N; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Ottl J; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Rigollier P; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Roman D; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Schnell C; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Sedrani R; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Shimizu T; National Cancer Center Hospital, Tokyo, Japan.
  • Stringer R; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Vaupel A; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Voshol H; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Wessels P; Novartis Pharma AG, Basel, Switzerland.
  • Widmer T; Novartis Pharma AG, Basel, Switzerland.
  • Wilcken R; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Xu K; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Zecri F; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Farago AF; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Cotesta S; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Brachmann SM; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Cancer Discov ; 12(6): 1500-1517, 2022 06 02.
Article en En | MEDLINE | ID: mdl-35404998
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Inhibidores Enzimáticos / Indazoles / Neoplasias Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Inhibidores Enzimáticos / Indazoles / Neoplasias Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos